von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

[1]  T. Choueiri,et al.  Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy , 2007, Cancer.

[2]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[3]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[4]  T. Choueiri,et al.  Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  T. Choueiri,et al.  The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. , 2006, Seminars in oncology.

[6]  K. Chew,et al.  Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status , 2006, BJU international.

[7]  S. Hirohashi,et al.  Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues , 2006, International journal of cancer.

[8]  M. Tan,et al.  The von Hippel-Lindau gene mutation is associated with the good-prognosis profiling subtype of clear cell renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[10]  Frederick L. Baehner,et al.  Bladder Cancer Outcome and Subtype Classification by Gene Expression , 2005, Clinical Cancer Research.

[11]  Joon-Oh Park,et al.  Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. , 2005, Oncology reports.

[12]  T. Choueiri,et al.  Evolving role of pegylated interferons in metastatic renal cell carcinoma , 2003, Expert review of anticancer therapy.

[13]  E. Messing,et al.  Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. , 2003, The Journal of urology.

[14]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[15]  O. Ogawa,et al.  Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. , 2003, Urology.

[16]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[17]  T. Shuin,et al.  Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters , 2002, Genes, chromosomes & cancer.

[18]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[19]  P. Schirmacher,et al.  VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. , 2000, Cancer research.

[20]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.